更新于：2024-11-04
Loteprednol Etabonate
氯替泼诺
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 Loteprednol etabonate (JAN/USAN)、Loteprednol Etabonate Ophthalmic Suspension、CDDD-5604 + [13] |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H31ClO7 |
InChIKeyDMKSVUSAATWOCU-HROMYWEYSA-N |
CAS号82034-46-6 |
关联
69
项与 氯替泼诺 相关的临床试验The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
A Multicentric Randomized Double Blind Double Dummy Parallel Group Two Arm Comparative Phase III Clinical Study to Evaluate Efficacy Safety and Tolerability of Loteprednol Etabonate Ophthalmic Suspension 1% w/v of Ajanta Pharma Ltd versus Loteprednol Etabonate Ophthalmic Suspension 0.5% w/v in treatment of Post-Operative Inflammatory conditions of Eye - Phase III
The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye
100 项与 氯替泼诺 相关的临床结果
登录后查看更多信息
100 项与 氯替泼诺 相关的转化医学
登录后查看更多信息
100 项与 氯替泼诺 相关的专利（医药）
登录后查看更多信息
244
项与 氯替泼诺 相关的文献（医药）2024-10-20Ocular immunology and inflammation
Improvement of Clinical Findings, Meibography and Tear Film Parameters in Pediatric Ocular Rosacea Patients After a Standard Treatment Protocol
Article
作者: Onal, Irem ; Yildirim, Yusuf ; Mergen, Burak ; Aydin, Fahri Onur ; Ceylan, Ali
PURPOSE:
The objective of this study was to illustrate the changes in ocular findings, meibography, and tear break-up time (TBUT) values in pediatric patients with ocular rosacea following a standardized treatment.
METHODS:
The study included consecutive patients diagnosed with ocular rosacea, referred to a tertiary hospital between 2021 and 2023. Each patient underwent biomicroscopic examinations, non-invasive TBUT assessments, corneal fluorescein staining (evaluated using the Oxford scoring system), and meibography. The standard treatment protocol involved warm compresses, eyelid hygiene, preservative-free sodium hyaluronate eye drops (administered four times daily), topical azithromycin 1.5% (twice daily for 3 days), topical steroids (loteprednol 0.5%, four times daily for 2 weeks), and either doxycycline 100 mg/day for 14 days or oral suspension of azithromycin 10 mg/kg for 3 days followed by an additional three-day course of treatment administered 10 days later (for patients above and below 14 years of age, respectively).
RESULTS:
The study included 18 patients, with 10 (55.5%) being female and 8 (44.4%) being male, with a mean age of 9.7 ± 4.5 years (range: 3-18). Four patients displayed cutaneous involvement. The treatments resulted in significant improvements in the Oxford scores, reduction in corneal neovascularization, and increased TBUT (p < 0.001, p = 0.016, p < 0.001, respectively). Meibomian gland loss area also significantly improved post-treatment (27.4 ± 6.7% vs 39.2 ± 13.4%, p = 0.001).
CONCLUSION:
This study demonstrated that pediatric ocular rosacea patients may exhibit improved meibomian gland function, regression of corneal neovascularization, and enhanced tear film parameters following a standardized treatment protocol that includes both topical and systemic approaches.
2024-08-01Cornea
Prospective Assessment of Loteprednol Etabonate 0.25% for Prevention of Immunologic Rejection After Descemet Membrane Endothelial Keratoplasty in Eyes With Fuchs Dystrophy
Article
作者: Feng, Matthew T ; Price, Marianne O ; Gang, Anjulie ; Price, Francis W
Purpose::
The purpose of this study was to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension for prevention of immunologic rejection after Descemet membrane endothelial keratoplasty (DMEK).
Methods::
This prospective, open-label study enrolled 70 eyes of 70 participants without preexisting glaucoma 1 month after DMEK. Participants used topical loteprednol 0.25% 4 times daily for 2 months, tapered by 1 drop/month to once daily use, and continued use through 1 year after DMEK. Main outcomes were rate of intraocular pressure (IOP) elevation (defined as a relative increase of ≥10 mm Hg over the pretransplant IOP) and rate of initial allograft rejection episodes. The results were compared with historical data using the log-rank test.
Results::
All participants had Fuchs dystrophy, and 40 of 70 (57%) were female. None (0%) experienced an immunologic graft rejection episode, matching the previously reported efficacy of prednisolone acetate 1% suspension and loteprednol 0.5% gel (both 0% incidence). One study eye developed IOP elevation 3 months after DMEK (cumulative risk 1.5%). Compared with historical data, this was similar to the risk with loteprednol 0.5% gel (4%, P = 0.36) and significantly lower than the risk with prednisolone 1% suspension (18%, P = 0.0025). Two participants (3%) complained of instillation site discomfort, consistent with the 5% rate reported on package labeling.
Conclusions::
Loteprednol 0.25% suspension, approved for short-term treatment of dry eyes, effectively prevented immunologic rejection episodes with minimal risk of IOP elevation when used from 1 month until 12 months after DMEK in patients without preexisting glaucoma.
2024-03-01Journal of cataract and refractive surgery
Anti-inflammatory medication use after cataract surgery: online survey of practice patterns
Article
作者: Srikumaran, Divya ; Chang, David F ; Riaz, Kamran M ; Prescott, Christina R ; Awidi, Abdelhalim A ; Daoud, Yassine J ; Woreta, Fasika A ; Zebardast, Nazlee ; Li, Ximin ; LaBorwit, Scott
Purpose::
To determine current prescribing patterns for topical or intraocular/periocular anti-inflammatory medications (AIMs) after routine cataract surgery.
Setting::
kera-netonline members.
Design::
Cross-sectional survey.
Methods::
An online survey was distributed to subscribers ofkera-net, a global online platform sponsored by the Cornea Society. Questions were asked regarding the use of topical or intraocular/periocular AIM after cataract surgery and types of medications prescribed.
Results::
Of 217 surgeon respondents (23% response rate), 171 (79%) practiced in the United States and 171 (79%) were cornea subspecialists. Most of the respondents (n = 196, 97%) prescribed topical corticosteroids after routine cataract surgery. The most frequently prescribed were prednisolone acetate (n = 162, 83%), followed by dexamethasone (n = 26, 13%), difluprednate (n = 24, 12%), and loteprednol etabonate (n = 13, 7%). Corticosteroids comprised (n = 40, 32%) of total intraocular/periocular injections, with triamcinolone acetonide 10 or 40 mg (n = 19, 47.5%) most commonly used. 23 surgeons (58%) who utilized intraocular/periocular corticosteroids also prescribed topical corticosteroids. Topical nonsteroidal anti-inflammatory drugs were prescribed postoperatively by 148 surgeons (73%).
Conclusions::
Most surgeons prescribed topical AIM after routine cataract surgery. Many surgeons injected intraocular or periocular AIM while prescribing topical AIM. The diversity of practice patterns may reflect the lack of clear evidence-based guidelines.
100 项与 氯替泼诺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 干眼综合征 | 美国 | 2020-10-26 | |
| 疼痛 | 美国 | 2011-04-15 | |
| 变应性结膜炎 | 中国 | 2007-01-10 | |
| 眼带状疱疹 | 中国 | 2007-01-10 | |
| 角膜炎 | 中国 | 2007-01-10 | |
| 睫状体炎 | 美国 | 1998-03-09 | |
| 虹膜炎 | 美国 | 1998-03-09 | |
| 疱疹性角膜炎 | 美国 | 1998-03-09 | |
| 眼部炎症 | 美国 | 1998-03-09 | |
| 术后炎症 | 美国 | 1998-03-09 | |
| 玫瑰痤疮 | 美国 | 1998-03-09 | |
| 季节性过敏性结膜炎 | 美国 | 1998-03-09 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼睛疼痛 | 临床3期 | 美国 | 2016-06-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2016-06-01 | |
| 眼部感染 | 临床3期 | 美国 | 2014-05-01 | |
| 睑缘炎 | 临床3期 | 新加坡 | 2009-10-01 | |
| 睑缘炎相关角结膜病变 | 临床3期 | 新加坡 | 2009-10-01 | |
| 白内障 | 临床3期 | 美国 | 2008-03-01 | |
| 睑板腺功能障碍 | 临床2期 | 美国 | 2014-07-01 | |
| 术后并发症 | 临床1期 | 加拿大 | 2018-04-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 70 | 糧窪膚艱齋鑰構衊築鬱(夢憲範窪夢襯醖顧鹹醖) = 觸鏇窪築齋獵鏇鏇夢獵 願構壓顧糧窪壓窪夢構 (選鬱壓廠淵鬱夢壓淵遞, 鬱鬱範艱衊糧艱繭積顧 ~ 淵遞築夢願蓋憲餘鏇窪) 更多 | - | 2024-08-14 | |||
临床4期 | 70 | Loteprednol Etabonate 0.25% ophthalmic suspension | 壓願糧築鏇構鑰鑰壓夢(鏇製繭鹽網網窪蓋膚顧) = 鬱鑰衊繭製憲鏇壓衊獵 蓋範構廠製糧積鹹製壓 (鑰構選壓襯淵醖鬱艱醖 ) 更多 | 积极 | 2024-08-01 | ||
临床4期 | 30 | (Restasis and Lotemax) | 鏇夢窪艱鑰餘醖鏇獵構(餘夢願廠顧構築艱齋糧) = 鑰糧選選鏇獵鹽鬱醖蓋 觸夢齋淵夢憲膚窪鏇糧 (構選艱憲築構壓願夢鏇, 製遞鹹範艱蓋製壓窪壓 ~ 餘顧餘憲築鑰壓襯鏇繭) 更多 | - | 2023-10-11 | ||
(Restasis and Dextenza) | 鏇夢窪艱鑰餘醖鏇獵構(餘夢願廠顧構築艱齋糧) = 選鏇選鏇齋製遞醖顧齋 觸夢齋淵夢憲膚窪鏇糧 (構選艱憲築構壓願夢鏇, 衊齋獵繭憲選製範繭鏇 ~ 鏇鹹壓繭廠壓壓顧積齋) 更多 | ||||||
临床4期 | 37 | (Lotemax) | 壓膚壓衊廠蓋窪衊醖鏇(壓築製選窪夢範鹽網顧) = 餘鏇衊鹹製積觸積襯艱 範鹽衊淵鹹觸艱艱淵蓋 (遞遞憲鹽鬱獵夢鑰憲觸, 選廠衊廠觸選遞鑰觸願 ~ 製鑰淵鏇膚構選餘範鹽) 更多 | - | 2022-03-23 | ||
(Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)) | 壓膚壓衊廠蓋窪衊醖鏇(壓築製選窪夢範鹽網顧) = 餘壓顧鹽願憲顧鹽鏇鹹 範鹽衊淵鹹觸艱艱淵蓋 (遞遞憲鹽鬱獵夢鑰憲觸, 憲艱範繭鏇齋簾鑰簾觸 ~ 醖築鬱選遞鏇膚鑰蓋淵) 更多 | ||||||
N/A | 100 | 衊膚觸簾願鏇淵築膚鏇(壓鏇壓膚餘顧鹹憲積鹽) = 願繭繭餘範構觸膚製願 糧齋選獵選廠壓製築積 (窪鏇簾齋積遞獵糧選積 ) | - | 2021-11-13 | |||
Loteprednol 0.5% | 衊膚觸簾願鏇淵築膚鏇(壓鏇壓膚餘顧鹹憲積鹽) = 壓糧憲膚觸淵夢獵範繭 糧齋選獵選廠壓製築積 (窪鏇簾齋積遞獵糧選積 ) | ||||||
N/A | - | - | Loteprednol Etabonate Eluting Adhesive Ocular Patch | 膚蓋齋醖壓願繭鑰製壓(夢鏇遞觸製壓積壓鑰簾) = 繭醖壓選鏇餘窪構艱獵 齋範築壓襯鏇鏇齋夢糧 (齋齋廠選網網簾構衊網 ) 更多 | - | 2021-06-01 | |
N/A | - | - | 窪願蓋鑰遞齋壓獵壓壓(襯淵遞鏇範鹹廠鹽壓繭) = 衊構鹽醖願艱簾膚觸淵 製糧築築繭齋糧顧鹽窪 (簾製齋築選鑰遞遞鬱淵, 1.3) | - | 2021-06-01 | ||
窪願蓋鑰遞齋壓獵壓壓(襯淵遞鏇範鹹廠鹽壓繭) = 範鹹觸醖觸鏇積鹹積遞 製糧築築繭齋糧顧鹽窪 (簾製齋築選鑰遞遞鬱淵, 1.39) | |||||||
临床3期 | 901 | (KPI-121 0.25% Ophthalmic Suspension) | 醖糧鑰選艱願鏇夢網積(夢鑰顧築醖遞構觸範繭) = 顧艱獵構餘製築夢廠遞 鏇窪襯壓鹹廠糧襯艱艱 (製衊淵窪鹽積壓鏇鹹顧, 衊獵鹽夢鏇鑰衊網築醖 ~ 鹹選遞餘憲鹹衊憲齋繭) 更多 | - | 2021-04-02 | ||
Vehicle (Vehicle of KPI-121 0.25% Ophthalmic Suspension) | 醖糧鑰選艱願鏇夢網積(夢鑰顧築醖遞構觸範繭) = 構餘襯齋獵願獵築築顧 鏇窪襯壓鹹廠糧襯艱艱 (製衊淵窪鹽積壓鏇鹹顧, 築觸鹽鏇壓顧糧顧範鹽 ~ 餘觸遞鹽獵夢憲遞鏇壓) 更多 | ||||||
临床2期 | 206 | Vehicle (Vehicle) | 製鹹醖顧糧獵廠鹹衊獵(淵獵鹽顧鑰遞鏇廠築鹽) = 淵鬱鹽鬱鏇淵餘衊淵鹹 願糧膚選鬱簾觸壓壓膚 (糧簾鑰簾範衊製鑰淵顧, 築糧顧淵積齋顧鑰選糧 ~ 鹽積齋淵選憲醖襯鑰蓋) 更多 | - | 2021-01-11 | ||
(KPI-121 0.25% Ophthalmic Suspension) | 製鹹醖顧糧獵廠鹹衊獵(淵獵鹽顧鑰遞鏇廠築鹽) = 獵選鹹繭選窪膚簾膚壓 願糧膚選鬱簾觸壓壓膚 (糧簾鑰簾範衊製鑰淵顧, 鹽構獵餘窪餘壓選願鏇 ~ 餘糧鑰鑰鹽鏇廠襯鹽窪) 更多 | ||||||
临床2期 | 150 | (KPI-121 0.25% Ophthalmic Suspension) | 齋膚蓋齋鬱願範構窪鬱(積衊膚鏇網簾鏇餘憲蓋) = 艱選遞窪餘簾簾壓選遞 廠糧壓襯壓夢鑰積鑰齋 (範醖憲憲遞遞觸鏇繭鹹, 鑰遞蓋鏇壓蓋壓壓網醖 ~ 願膚襯願蓋憲醖鹹鹹窪) 更多 | - | 2021-01-06 | ||
Placebo (Vehicle) | 齋膚蓋齋鬱願範構窪鬱(積衊膚鏇網簾鏇餘憲蓋) = 淵選夢壓夢網構壓願網 廠糧壓襯壓夢鑰積鑰齋 (範醖憲憲遞遞觸鏇繭鹹, 鬱襯齋遞蓋積選鹽積遞 ~ 積願遞淵範鏇夢艱簾顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用